Nerve-Selective Therapy for Painful Knee Osteoarthritis: First-in-Human Safety and Preliminary Effectiveness
Journal of Cartilage & Joint Preservation · 2026-11 · 100331
DOI: 10.1016/j.jcjp.2026.100331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cartilage & Joint Preservation, 2026-11. Verfasst von Murray Taverner und 9 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Introduction
Knee osteoarthritis (KOA) is a multifactorial, degenerative joint disease associated with chronic pain and functional disability. There is a therapeutic gap of non-surgical, minimally invasive interventional treatments that provide adequate pain relief.
Objective
This study assessed the safety and preliminary effectiveness of a novel, nerve-selective, biomaterial (BXT-786) to provide prolonged analgesia when delivered around the articular nerves in subjects with symptomatic KOA.
Methods
This two-part, single-cohort, open-label pilot study enrolled 16 subjects with Kellgren-Lawrence grade 3 or 4 KOA and a diagnostic block that confirmed the knee as the primary pain generator, at three sites in Australia and the United States (ACTRN12621001667808). Safety was assessed through adverse events (AEs). Preliminary effectiveness was evaluated through changes in pain scores and brief pain inventory, and identification of time-to-onset and duration of pain relief.
Results
Mean time-to-onset of pain relief reported at study visits was 6.9 (± 1.6 SD) days. At end of study, subjects reported a mean pain reduction of 53.3% (95% CI: 34.9 - 71.6%). Of the 39 treatment-emergent AEs and 22 device-related AEs, 79.5% and 81.8%, respectively, were mild or moderate, and related to injection site pain and bruising. Treatment-emergent AEs included 7 severe and 1 serious but unrelated to BXT-786, and device-related AEs included 4 severe and none serious. Most severe and serious AEs resolved with no intervention.
Conclusion
BXT-786 therapy was feasible and well tolerated. Preliminary results demonstrated a reduction in knee pain within 2 weeks after treatment that persisted up to 12 weeks.
Förderung
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Taverner, M., Bates, D., Naidu, R., Kheireddine, Z., Gopinath, S., Curd, D., Fishman, M. A., Sidoti, C., Garibyan, L., & Anderson, R. R. (2026). Nerve-Selective Therapy for Painful Knee Osteoarthritis: First-in-Human Safety and Preliminary Effectiveness. Journal of Cartilage & Joint Preservation, 100331. https://doi.org/10.1016/j.jcjp.2026.100331
Vancouver
Taverner M, Bates D, Naidu R, Kheireddine Z, Gopinath S, Curd D, et al. Nerve-Selective Therapy for Painful Knee Osteoarthritis: First-in-Human Safety and Preliminary Effectiveness. Journal of Cartilage & Joint Preservation. 2026:100331. doi:10.1016/j.jcjp.2026.100331
BibTeX
@article{Taverner2026,
author = {Taverner, Murray and Bates, Daniel and Naidu, Ramana and Kheireddine, Zeinab and Gopinath, Sadhana and Curd, David and Fishman, Michael A. and Sidoti, Charles and Garibyan, Lilit and Anderson, Richard R.},
title = {Nerve-Selective Therapy for Painful Knee Osteoarthritis: First-in-Human Safety and Preliminary Effectiveness},
journal = {Journal of Cartilage & Joint Preservation},
year = {2026},
pages = {100331},
doi = {10.1016/j.jcjp.2026.100331}
}
EUVIMED